Clinical Trials & Research
Search Clinical Trials
|Title||Radiation Therapy With or Without Trastuzumab in Treating Women With Ductal Carcinoma In Situ Who Have Undergone Lumpectomy|
|Description||The purpose of this trial is to study radiation therapy to see how well it works compared with or without trastuzumab in treating women with ductal carcinoma in situ who have undergone lumpectomy.|
Monoclonal antibodies, such as trastuzumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Radiation therapy uses high-energy x-rays to kill tumor cells.
It is not yet known whether radiation therapy is more effective with or without trastuzumab in treating ductal carcinoma in situ.
|Eligibility Criteria||To be eligible for this study, patients must meet several criteria, including but not limited to the following:|
* Patient must be Female and 18 Years or older
* Patient must have histologically confirmed ductal carcinoma in situ (DCIS)
* Life expectancy = 10 years (excluding diagnosis of DCIS)
|Principal Investigator||Madhur Garg, MD|
|Contact Name||Karen Fehn, RN|
|Current Trial Type||Interventional|
|Montefiore Clinical Trial||No|
|CHAM Clinical Trial||No|